Weekend Links
Emily Oster on the power of nuance in public health.When did sustained economic growth begin?NYT: Rethinking drinking?Lex Fridman interviews Javier Milei (en español).Dumbest state “law” of the month
Read More
Why We Need to Rethink Private Practice Mental Health Care
No single provider should be expected to do everything, and no patient should have to navigate a fragmented system alone. A team-based model makes care more accessible, more effective, and more supportive for both patients and the providers who care for them. The post Why We Need to Rethink Private Practice Mental Health Care appeared…
How does socioeconomic status—and how it is measured—impact wait times?
Many studies have found that patients with lower socioeconomic status (SES) have worse access to care. For instance, patients from lower SES have longer wait times (see review papers Landi et al. 2018 and Siciliani 2016). One key question is whether these disparities depend on how socioeconomic status is measured: at the individual level or…
Smoking Cessation’s Quiet Design Failure
The gap between how nicotine use has evolved and how cessation treatment has evolved is a meaningful part of why quit rates have plateaued. The post Smoking Cessation’s Quiet Design Failure appeared first on MedCity News.
Using ‘Digital Twins’ to Address Chronic Metabolic Conditions
Twin Health CMO Lisa Shah, M.D., describes how her company makes highly personalized recommendations to help users reach goals such as a lower A1C
Journalists Dig Into Government Shutdown and Rural Doctor Drought
KFF Health News chief Washington correspondent Julie Rovner appeared on CNN’s “Quest Means Business” to discuss the Affordable Care Act subsidies at the core of the government shutdown on Oct. 2. Rovner also appeared on NPR’s “Morning Edition” to discuss the subsidies on Oct. 7. Click here to watch Rovner on “Quest Means Business.” Click…
Novartis RNA Med From $12B Deal Keeps Building Case to Become First Therapy for Rare Muscle Disease
Novartis said its RNA therapy del-brax met goals of a Phase 1/2 study in facioscapulohumeral muscular dystrophy (FSHD), an inherited muscle disorder that currently has no FDA-approved medicines. Del-brax is one of three RNA therapies from Novartis’s $12 billion acquisition of Avidity Biosciences. The post Novartis RNA Med From $12B Deal Keeps Building Case to…
How Medicare Pays Medicare Advantage Plans: Issues and Policy Options
This brief explains how Medicare Advantage payments are determined and provides an overview of policy options to change the Medicare Advantage payment system.
Bouncing Back From Trial Failure, Travere Wins First FDA Approval in Rare Kidney Disease
Travere Therapeutics’ Filspari is now the first FDA-approved drug for focal segmental glomerulosclerosis (FSGS), a rare kidney disease. Analysts project the pill will become a blockbuster seller. The post Bouncing Back From Trial Failure, Travere Wins First FDA Approval in Rare Kidney Disease appeared first on MedCity News.
With $4.7B Akero Acquisition, Novo Nordisk Maps Out Broader Strategy in MASH and Beyond
Novo Nordisk is acquiring Akero Therapeutics for drug candidate efruxifermin, which executive say could be first and best in the emerging class of FGF21 analogs for the fatty liver disease MASH. The deal comes months after Novo’s internal FGF21 drug candidate failed a Phase 2 trial. The post With $4.7B Akero Acquisition, Novo Nordisk Maps…